Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma

Ricke J., Schinner R., Seidensticker M., Gasbarrini A., van Delden O. M., Amthauer H., ...More

JOURNAL OF HEPATOLOGY, vol.75, no.6, pp.1387-1396, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 75 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.1016/j.jhep.2021.07.037
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1387-1396
  • Keywords: ALBI score, Hepatocellular carcinoma, Radioembolization, Selective internal radiation therapy, Sorafenib, RADIOEMBOLIZATION, DISEASE, PREVENTION, Y-90
  • Hacettepe University Affiliated: Yes


Background & Aims: SORAMIC is a previously published randomised controlled trial assessing survival in patients with advanced hepatocellular carcinoma who received sorafenib with or without selective internal radiation therapy (SIRT). Based on the per-protocol (PP) population, we assessed whether the outcome of patients receiving SIRT+sorafenib vs. sorafenib alone was affected by adverse effects of SIRT on liver function.